MA26735A1 - Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26735A1
MA26735A1 MA25979A MA25979A MA26735A1 MA 26735 A1 MA26735 A1 MA 26735A1 MA 25979 A MA25979 A MA 25979A MA 25979 A MA25979 A MA 25979A MA 26735 A1 MA26735 A1 MA 26735A1
Authority
MA
Morocco
Prior art keywords
crystalline forms
pharmaceutical compositions
compositions containing
preparation
new crystalline
Prior art date
Application number
MA25979A
Other languages
English (en)
Inventor
John Rafka Robert
James Morton Barry
John Meldrum Allen Douglas
Brendan Ragan Colman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26735A1 publication Critical patent/MA26735A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DES FORMES CRISTALLINES NOUVELLES D'UN COMPOSÉS DE FORMULE 1 ELLE CONCERNE ÉGALEMENT UN PEOCÉDÉ POUR LEUR PRÉPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. - APPLICATION : UTILISATION DE CES FORMES CRISTALLINES ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. - APPLICATIONS : UTILISATION DE CES FORMES CRISTALLINES ET COMPOSITIONS POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES ET D'INFECTIONS PAR DES PROTOZOAIRES.
MA25979A 1999-05-18 2000-05-17 Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant MA26735A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13464499P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
MA26735A1 true MA26735A1 (fr) 2004-12-20

Family

ID=22464300

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25979A MA26735A1 (fr) 1999-05-18 2000-05-17 Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (43)

Country Link
US (1) US6583274B1 (fr)
EP (1) EP1189912B1 (fr)
JP (1) JP3897983B2 (fr)
KR (1) KR100474229B1 (fr)
CN (1) CN1203084C (fr)
AP (1) AP2001002325A0 (fr)
AR (1) AR020030A1 (fr)
AT (1) ATE392427T1 (fr)
AU (1) AU772283B2 (fr)
BG (1) BG106150A (fr)
BR (1) BR0011300A (fr)
CA (1) CA2372206C (fr)
CZ (1) CZ20014120A3 (fr)
DE (1) DE60038610T2 (fr)
DK (1) DK1189912T3 (fr)
DZ (1) DZ3043A1 (fr)
EA (1) EA003417B1 (fr)
ES (1) ES2302689T3 (fr)
GT (1) GT200000072A (fr)
HK (1) HK1045521B (fr)
HN (1) HN2000000056A (fr)
HR (1) HRP20010849A2 (fr)
HU (1) HUP0201341A3 (fr)
IL (2) IL145946A0 (fr)
IS (1) IS6127A (fr)
MA (1) MA26735A1 (fr)
MX (1) MXPA01011914A (fr)
MY (1) MY133397A (fr)
NO (1) NO320195B1 (fr)
NZ (1) NZ514765A (fr)
OA (1) OA11876A (fr)
PA (1) PA8495001A1 (fr)
PE (1) PE20010151A1 (fr)
PL (1) PL353316A1 (fr)
PT (1) PT1189912E (fr)
SK (1) SK16472001A3 (fr)
TN (1) TNSN00103A1 (fr)
TW (1) TWI225066B (fr)
UA (1) UA67842C2 (fr)
UY (1) UY26144A1 (fr)
WO (1) WO2000069874A1 (fr)
YU (1) YU76601A (fr)
ZA (1) ZA200109420B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
MXPA02007305A (es) 2000-01-27 2002-11-29 Pfizer Prod Inc Composiciones antiboticas de azalida.
JP4104463B2 (ja) * 2001-04-27 2008-06-18 ファイザー・プロダクツ・インク ４’’−置換された−９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシン誘導体を製造するための方法
EP1435359A1 (fr) * 2002-12-31 2004-07-07 Alembic Limited Procédé de purification de roxithromycin
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
MA32997B1 (fr) * 2009-01-30 2012-01-02 Glaxo Group Ltd Macrolide anti-inflammatoire
EP2402355A1 (fr) * 2010-07-01 2012-01-04 Novartis AG Formes cristallines anhydres II et III de tulathromycin
WO2013013834A1 (fr) 2011-07-27 2013-01-31 Farma Grs, D.O.O. Nouvelles formes cristallines de tulathromycine
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN109942652B (zh) * 2017-12-21 2022-04-26 洛阳惠中兽药有限公司 一种莱柯霉素晶型ⅰ及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.

Also Published As

Publication number Publication date
HRP20010849A2 (en) 2003-04-30
IL145946A (en) 2007-06-17
KR100474229B1 (ko) 2005-03-08
KR20020007415A (ko) 2002-01-26
CN1351607A (zh) 2002-05-29
AP2001002325A0 (en) 2001-12-31
HK1045521A1 (en) 2002-11-29
NO20015598D0 (no) 2001-11-16
IL145946A0 (en) 2002-07-25
TNSN00103A1 (fr) 2005-11-10
GT200000072A (es) 2001-11-08
SK16472001A3 (sk) 2003-02-04
HK1045521B (zh) 2005-12-09
ES2302689T3 (es) 2008-08-01
HN2000000056A (es) 2001-02-02
EP1189912A1 (fr) 2002-03-27
TWI225066B (en) 2004-12-11
MXPA01011914A (es) 2002-05-06
CA2372206A1 (fr) 2000-11-23
HUP0201341A3 (en) 2003-03-28
EP1189912B1 (fr) 2008-04-16
CA2372206C (fr) 2006-01-10
CZ20014120A3 (cs) 2003-01-15
NO320195B1 (no) 2005-11-14
UA67842C2 (uk) 2004-07-15
EA003417B1 (ru) 2003-04-24
DE60038610T2 (de) 2009-06-25
YU76601A (sh) 2004-09-03
DE60038610D1 (de) 2008-05-29
JP2002544283A (ja) 2002-12-24
NO20015598L (no) 2002-01-08
CN1203084C (zh) 2005-05-25
BR0011300A (pt) 2002-02-26
US6583274B1 (en) 2003-06-24
DZ3043A1 (fr) 2004-03-27
MY133397A (en) 2007-11-30
EA200100984A1 (ru) 2002-06-27
UY26144A1 (es) 2000-12-29
OA11876A (en) 2006-03-27
IS6127A (is) 2001-10-26
DK1189912T3 (da) 2008-06-30
BG106150A (bg) 2002-05-31
AU3572900A (en) 2000-12-05
ZA200109420B (en) 2002-11-15
PA8495001A1 (es) 2002-02-21
AU772283B2 (en) 2004-04-22
AR020030A1 (es) 2002-03-27
HUP0201341A2 (en) 2002-08-28
WO2000069874A1 (fr) 2000-11-23
ATE392427T1 (de) 2008-05-15
PT1189912E (pt) 2008-05-16
PL353316A1 (en) 2003-11-17
NZ514765A (en) 2004-05-28
JP3897983B2 (ja) 2007-03-28
PE20010151A1 (es) 2001-02-08

Similar Documents

Publication Publication Date Title
MA26703A1 (fr) Macrolides antibiotiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24729A1 (fr) Macrolides nouveaux.
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
MA26717A1 (fr) Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
EA199901014A1 (ru) C-4"-замещенные макролидные производные
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
TR199902995T2 (xx) 9-Oksim eritromisin t�revleri
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99227A1 (fr) Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
MA26735A1 (fr) Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
MA24685A1 (fr) Derives d'erythromycine tricycliques nouveaux, procede pour leur preparation et composition les contenant
CA2266759A1 (fr) Derives 3-mercaptoacetylamino-1,5-substitue-2-oxo-azepane, utilises comme inhibiteurs de metalloproteinase matrice
TNSN99221A1 (fr) Derive d'indole nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
CA2107485A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TNSN99083A1 (fr) Derives d'hygromycine a et leur procede de preparation.
TNSN98061A1 (fr) Derives d'erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26734A1 (fr) Derives de 1-trifluoromethyl -4-hydroxy- 7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26626A1 (fr) Derives de 2"-desoxy-hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26705A1 (fr) Derives d'hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN87077A1 (fr) Procede de preparation d'une composition pour le traitement des infections bacteriennes